Loading...
•
Sep 30, 2021
Pacira Q3 2021 Earnings Report
Reported preliminary net product sales for October 2021.
Key Takeaways
Pacira BioSciences reported preliminary unaudited net product sales for October 2021, with EXPAREL sales at $42.5 million and iovera° sales at $1.2 million. The company is confident in strong growth in the fourth quarter due to a reduction in pandemic-related challenges.
EXPAREL net product sales reached $42.5 million in October 2021.
iovera° net product sales were $1.2 million for October 2021.
EXPAREL average daily sales for October 2021 were 109% of October 2020.
The company anticipates topline annual growth in the high teens with operating margins exceeding 50% within 5 years.
Revenue by Segment
Forward Guidance
Pacira BioSciences anticipates strong growth in the fourth quarter and expects to deliver topline annual growth in the high teens with operating margins that exceed 50 percent by the end of their 5-year planning period.
Positive Outlook
- Reduction in pandemic-related challenges.
- Confident in outlook for strong growth in the fourth quarter.
- Integration planning continues to progress.
- ZILRETTA is expected to provide significant operational synergies.
- ZILRETTA is expected to provide accretion and growth potential.
Challenges Ahead
- Elective surgery market normalization timeline is unclear.
- Potential for recurrence of restrictions on elective procedures due to COVID-19 variant strains.
- Financial information included is preliminary and unaudited.
- Financial information is subject to adjustment.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...